Literature DB >> 21652770

Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.

Masaki Shiota1, Ario Takeuchi, YooHyun Song, Akira Yokomizo, Eiji Kashiwagi, Takeshi Uchiumi, Kentaro Kuroiwa, Katsunori Tatsugami, Naohiro Fujimoto, Yoshinao Oda, Seiji Naito.   

Abstract

The androgen receptor (AR) is well known to play a central role in the pathogenesis of prostate cancer (PCa). In several studies, AR was overexpressed in castration-resistant PCa (CRPC). However, the mechanism of AR overexpression in CRPC is not fully elucidated. Y-box binding protein-1 (YB-1) is a pleiotropic transcription factor that is upregulated in CPRC. We aimed to elucidate the role of YB-1 in castration resistance of PCa and identify therapeutic potential of targeting YB-1. Using immunohistochemistry, we found that nuclear YB-1 expression significantly correlated with the Gleason score and AR expression in PCa tissues. In PCa cells, YB-1 regulated AR expression at the transcriptional level. Furthermore, YB-1 expression and nuclear localization were upregulated in CRPC cells. Overexpression of AR, as well as YB-1, conferred castration-resistant growth in LNCaP and 22Rv1 cells. Conversely, knocking down YB-1 resulted in suppressed cell growth and induced apoptosis, which was more efficient than knocking down AR in LNCaP cells. In other types of PCa cells, such as CRPC cells, knocking down YB-1 resulted in a significant reduction of cell growth. In conclusion, these findings suggested that YB-1 induces castration resistance in androgen-dependent PCa cells via AR expression. Thus, YB-1 may be a promising therapeutic target for PCa, as well as CRPC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21652770     DOI: 10.1530/ERC-11-0017

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  25 in total

1.  Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.

Authors:  Yong Wang; Yajing Chen; Hua Geng; Can Qi; Yunde Liu; Dan Yue
Journal:  Tumour Biol       Date:  2015-04-17

2.  Efficacy of androgen deprivation therapy and the role of oxidative stress.

Authors:  D K Price
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

Review 3.  Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.

Authors:  Zhonglin Cai; Weijie Chen; Jianzhong Zhang; Hongjun Li
Journal:  Int Urol Nephrol       Date:  2018-08-20       Impact factor: 2.370

4.  Y-box-binding protein 1 contributes to IL-7-mediated survival signaling in B-cell precursor acute lymphoblastic leukemia.

Authors:  Amina Kariminia; Sabine M Ivison; Vivian M Leung; Susanna Sung; Nicole Couto; Jacob Rozmus; Nina Rolf; Aru Narendran; Sandra E Dunn; Gregor S D Reid; Kirk R Schultz
Journal:  Oncol Lett       Date:  2016-11-28       Impact factor: 2.967

5.  Differential expression of the multidrug resistance 1 (MDR1) protein in prostate cancer cells is independent from anticancer drug treatment and Y box binding protein 1 (YB-1) activity.

Authors:  Madeleine Saupe; Lisa Rauschenberger; Melanie Preuß; Stefan Oswald; Sebastian Fussek; Uwe Zimmermann; Reinhard Walther; Cornelius Knabbe; Martin Burchardt; Matthias B Stope
Journal:  World J Urol       Date:  2014-12-28       Impact factor: 4.226

6.  IMPDH1/YB-1 Positive Feedback Loop Assembles Cytoophidia and Represents a Therapeutic Target in Metastatic Tumors.

Authors:  Hailong Ruan; Zhengshuai Song; Qi Cao; Dong Ni; Tianbo Xu; Keshan Wang; Lin Bao; Junwei Tong; Haibing Xiao; Wen Xiao; Gong Cheng; Zhiyong Xiong; Huageng Liang; Di Liu; Liang Wang; Tredan Olivier; Boyle Helen Jane; Hongmei Yang; Xiaoping Zhang; Ke Chen
Journal:  Mol Ther       Date:  2020-03-10       Impact factor: 11.454

7.  Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial-mesenchymal transition through targeting major vault protein (MVP).

Authors:  Lei Lou; Juan Wang; Fengzhu Lv; Guohui Wang; Yuehong Li; Lingxiao Xing; Haitao Shen; Xianghong Zhang
Journal:  Cell Oncol (Dordr)       Date:  2020-09-07       Impact factor: 6.730

Review 8.  The role of the p90 ribosomal S6 kinase family in prostate cancer progression and therapy resistance.

Authors:  Ryan Cronin; Greg N Brooke; Filippo Prischi
Journal:  Oncogene       Date:  2021-05-10       Impact factor: 9.867

Review 9.  A comprehensive review of the functions of YB-1 in cancer stemness, metastasis and drug resistance.

Authors:  Akram Alkrekshi; Wei Wang; Priyanka Shailendra Rana; Vesna Markovic; Khalid Sossey-Alaoui
Journal:  Cell Signal       Date:  2021-07-03       Impact factor: 4.850

10.  An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer.

Authors:  Miho Ushijima; Masaki Shiota; Takashi Matsumoto; Eiji Kashiwagi; Junichi Inokuchi; Masatoshi Eto
Journal:  Cancer Sci       Date:  2022-04-01       Impact factor: 6.518

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.